Lepu Medical stated at the earnings briefing that the implantable deep brain stimulator is expected to be approved for market launch soon and is likely to contribute revenue next year. The implantable cardiac contractility modulator is preparing to file for approval in the first and second quarters of next year. The neuroregulation business segment will provide new logic for the company's performance growth. In the context of centralized procurement, the company is committed to developing implantable medical devices with higher technological barriers and better market competition patterns in the field of major clinical demand diseases, thereby reducing the impact of centralized procurement policies on the company's business
